A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis

Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis

NCT05722964 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers

NCT06482190 ·Status: RECRUITING ·Phase: PHASE1

Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis

NCT07192939 ·Status: RECRUITING ·Phase: PHASE2

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

NCT05975983 ·Status: RECRUITING ·Phase: PHASE2

To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF

NCT05497284 ·Status: TERMINATED ·Phase: PHASE2

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

NCT01766817 ·Status: COMPLETED ·Phase: PHASE2

A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis

NCT05065190 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis

NCT05387785 ·Status: UNKNOWN ·Phase: PHASE1

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

NCT01203943 ·Status: TERMINATED ·Phase: PHASE2

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

NCT03287414 ·Status: TERMINATED ·Phase: PHASE2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects

NCT05912049 ·Status: UNKNOWN ·Phase: PHASE1

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

NCT04720443 ·Status: COMPLETED ·Phase: PHASE1

Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF

NCT06181370 ·Status: RECRUITING ·Phase: PHASE1

Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis

NCT01262001 ·Status: COMPLETED ·Phase: PHASE2

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01529853 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

NCT07036523 ·Status: RECRUITING ·Phase: PHASE2

Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)

NCT01769196 ·Status: TERMINATED ·Phase: PHASE2

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

NCT05321082 ·Status: COMPLETED ·Phase: PHASE3

A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis

NCT05349760 ·Status: WITHDRAWN ·Phase: PHASE2

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

NCT05570058 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

NCT06335303 ·Status: COMPLETED ·Phase: PHASE2

A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis

NCT06102083 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis

NCT05424887 ·Status: UNKNOWN ·Phase: PHASE2

A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.

NCT05361733 ·Status: RECRUITING ·Phase: PHASE1

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT01872689 ·Status: COMPLETED ·Phase: PHASE2